Canada: Life Sciences, Biotechnology & Nanotechnology

The 2026 annual Bloom Burton & Co. Healthcare Investor Conference—Canada's premier international forum for healthcare companies and investors—was held in late April in Toronto.

Health Canada released a notice to industry on April 24, 2026, outlining that manufacturers must use the Regulatory Enrolment Process (REP) and Common Electronic Submission Gateway (CESG) for medical device transactions as of April 1, 2026. As we previously reported, manufacturers of medical devices could voluntarily use the REP and CESG for medical device regulatory transactions as of July 2024.

In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).

pour déterminer si un titulaire de droits a omis de soumettre les renseignements exigés conformément à la Loi sur les brevets et au Règlementsur les médicaments brevetés.

Life sciences has transformed and the patent landscape is transforming with it. Platform technologies, from connectivity standards embedded in smart medical devices...

Les organismes réglementaires canadiens pourraient bientôt devoir se prononcer sur le rôle de l'intelligence artificielle (« IA ») autonome dans la prestation des soins de santé.

Below are Rx IP Update's most-read articles of 2025...

Below are Rx IP Update's most-read articles of 2025...

Health Canada's 2025 Red Tape Review has sparked significant regulatory reforms aimed at streamlining drug and medical device approvals through international harmonization. New draft guidance and proposed legislative changes promise to reduce clinical trial requirements for biosimilars, enable faster approvals through foreign reliance pathways, and eliminate redundant licensing requirements for medical device importers.